Fermata Advisors’s Starling Oncology STLN Stock Holding History

Fermata Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$80.1K	Sell	12,675 -125	-1%	-$747	0.02%	290
2026 Q2	$69.5K	Buy	+12,800	New	+$53.8K	0.01%	273

Other funds holding STLN

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Berkshire Money Management Dalton, Massachusetts $1.16B AUM 13.8% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fermata Advisors's STLN Position: Q3 2026 in Review

Fermata Advisors reduced its Starling Oncology (STLN) stake by 0.98% in Q3 2026, selling an estimated $747 and leaving 12,675 shares worth $80.1K. The position accounts for 0.02% of the portfolio, ranked #290.

Fermata Advisors first reported a position in STLN in Q2 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

Fermata Advisors held 12,675 shares of Starling Oncology worth $80.1K as of Q3 2026.
Fermata Advisors sold 125 Starling Oncology shares in Q3 2026, an estimated $747.
Starling Oncology made up 0.02% of Fermata Advisors's portfolio in Q3 2026, its #290 holding.
Fermata Advisors first reported a position in Starling Oncology in Q2 2026 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Fermata Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.